Top 10 OncoGrants This Week: Major Funding Opportunities Across Cancer Research

This week’s OncoGrants roundup brings together 10 standout funding opportunities spanning cancer immunotherapy, kidney cancer, melanoma, lymphoma, cholangiocarcinoma, ovarian cancer, and women’s cancers — with awards ranging from focused career-development support to more than $1 million in long-term research funding.

Career development is a major theme across this selection. Opportunities such as the CRI IGNITE Award, Lymphoma Research Foundation Clinical Investigator Career Development Award, and Victoria’s Secret Global Fund for Women’s Cancers Career Development Award are designed to help emerging investigators build independent research careers. At the other end of the spectrum, the CRI Lloyd J. Old STAR Program and Melanoma Research Alliance Established Investigator Award provide substantial support for established scientists pursuing ambitious and potentially transformative ideas.

Innovation and translation are equally prominent. The CRI Clinical Innovator supports investigator-led cancer immunotherapy trials, while the CRI Technology Impact Award backs high-risk technological concepts that could reshape the field. Disease-focused opportunities from the Cholangiocarcinoma Foundation, Kidney Cancer Research Program, and Conquer Cancer add major funding for biomarker discovery, translational research, and new approaches to treatment.

Whether you are transitioning toward research independence, developing an innovative technology, launching a clinical study, or leading an established cancer research programme, this week’s Top 10 OncoGrants offers high-impact opportunities across multiple stages of the oncology research career.

1. Victoria’s Secret Global Fund for Women’s Cancers Career Development Award 2026

The Victoria’s Secret Global Fund for Women’s Cancers Career Development Award, in partnership with Pelotonia and the American Association for Cancer Research, supports innovative research addressing breast and gynecologic cancers.

The award is designed to advance the careers of early-stage scientists conducting basic, translational, clinical, or population-sciences research related to the understanding, prevention, interception, early detection, diagnosis, or treatment of women’s cancers. Projects addressing cancer health disparities and strategies to improve equity in outcomes are especially encouraged.

Eligibility Criteria:

• Applicants must hold a PhD, MD, MD/PhD, or equivalent doctoral degree in a relevant field.
• Applicants must have started their first independent faculty position within six years of the grant start date.
• Up to 12 months of additional eligibility may be considered for parental leave or justified personal or family leave.
• Applicants must devote at least 75% of their total professional effort to research in breast cancer or a gynecologic cancer.
• Applicants cannot be employees or subcontractors of a U.S. federal government entity or for-profit private industry.
• Applicants cannot hold another AACR grant concurrently.

Funding Details:

• The award provides USD 206,000 over two years.
• Graduate-student tuition associated with education and training may be included.
• The recipient must devote at least 75% of their total effort to breast or gynecologic cancer research.
• Professional membership dues and expenses unrelated to the proposed project are not eligible.

Deadline:

• Application deadline: September 3, 2026, at 1:00 p.m. U.S. Eastern Time.
• Award decision: November 2026.
• Grant term begins: December 1, 2026.
• The anticipated two-year grant period runs through November 30, 2028.

Further Information:

• Eligible projects may address breast cancer or any gynecologic cancer through basic, translational, clinical, or population-sciences research.
• Proposals focused on cancer health disparities, unequal outcomes, and approaches to achieving equity are especially encouraged.
• Applications require a six-page research proposal, one-page statistical analysis plan, project milestones, biosketch, budget justification, institutional reference letter, and signed applicant checklist.
• Applications must be submitted through ProposalCentral using the official templates; altering templates or failing to follow formatting requirements may result in rejection without review.
• Eligibility and application questions should be directed to the AACR Research and Grants Administration team at grants@aacr.org.

2. Melanoma Research Alliance Established Investigator Award 2026–2027

The Melanoma Research Alliance Established Investigator Award supports experienced investigators conducting innovative preclinical, translational, or early clinical melanoma research.

Projects should have the potential to produce unusually high-impact, near-term advances in melanoma prevention, detection, diagnosis, or treatment. MRA prioritizes transformative research supported by a strong scientific rationale, rigorous methodology, and a credible pathway toward clinical application.

Eligibility Criteria:

• Applicants must hold a full-time faculty appointment at the level of Assistant Professor or an equivalent position, or higher.
• Applicants must work at an academic institution or another eligible nonprofit research organization.
• Principal Investigators must demonstrate clear evidence of an independent research program.
• Investigators do not need to have received formal training specifically in melanoma research.
• Previous MRA recipients must be current with all required scientific and financial reporting.
• Each investigator may serve as PI on only one MRA proposal across all award mechanisms and Special Opportunity Awards in the 2026–2027 cycle.
• Multiple proposals may be submitted from the same institution when each has a different PI and addresses a distinct scientific hypothesis.
• UK- and Israel-based Special Opportunity Awards are restricted to eligible investigators working in those countries.

Funding Details:

• The award provides up to USD 125,000 per year.
• The maximum award period is three years.
• The maximum total award is USD 375,000.
• MRA plans to provide at least USD 7.9 million in new funding across all mechanisms in the 2026–2027 cycle.

Deadline:

• Letter of Intent deadline: August 21, 2026, at 5:00 p.m. Eastern Time.
• Estimated LOI decisions: October 31, 2026.
• Invited full proposal deadline: December 10, 2026, at 5:00 p.m. Eastern Time.

Further Information:

• Applications are evaluated according to scientific and clinical importance, originality, rigor, feasibility, investigator qualifications, institutional support, and potential for rapid clinical benefit.
• Original and transformative projects with a strong scientific rationale and clear pathway toward improving melanoma prevention, detection, diagnosis, or treatment will receive priority.
• MRA also offers related Special Opportunity Awards in acral melanoma, uveal melanoma, and for eligible investigators based in the United Kingdom and Israel.
• Proposals must be submitted through ProposalCentral, and eligibility questions may be directed to science@curemelanoma.org.
• Official program information and application details: Visit the Melanoma Research Alliance 2026–2027 Request for Proposals page for the official RFP, application requirements, current deadlines, Special Opportunity details, and program updates.

3. CRI Lloyd J. Old STAR Program 2027

The CRI Lloyd J. Old STAR Program – Scientists TAking Risks – provides long-term, flexible funding to exceptional mid-career investigators pursuing transformative research at the forefront of cancer immunology and immunotherapy.

Unlike a traditional project-specific grant, the STAR Program supports outstanding scientists and their broader research vision, giving recipients the freedom to explore unconventional ideas, unexpected scientific directions, and high-risk approaches that could lead to major advances in immune-based cancer treatment.

Eligibility Criteria:

• Applicants must hold an MD, PhD, MD/PhD, or equivalent degree.
• Applicants must hold an eligible tenure-track academic or research position.
• For the January 2027 application cycle, eligible Assistant Professors must have been appointed on or before July 1, 2024.
• Tenure-track Associate Professors must have held that position for no more than three years.
• There are no citizenship restrictions.
• Research conducted at for-profit institutions is not eligible for CRI support.

Funding Details:

• The STAR Program provides USD 1.25 million over five years.
• Funding is flexible and is not tied to a single narrowly defined research project.
• Institutions may receive indirect costs of up to 10% of the total amount awarded.
• This means total support may reach approximately USD 1.375 million, including the maximum allowable indirect costs.
• Awards must begin on the first day of a month.

Deadline:

Application deadline: January 15, 2027, at 11:59 p.m. Eastern Time.
Interview invitations: Early March 2027.
Invited interviews: Spring 2027, with the exact date to be announced.
Earliest award activation: July 1, 2027.

Further Information:

• The program prioritizes investigators capable of asking important, non-obvious scientific questions, connecting ideas across disciplines, and pursuing unconventional approaches with transformative potential.
• Applications require a 300-word non-technical abstract, a research proposal of up to four pages describing ongoing work and plans for the next five years, and information on five major peer-reviewed publications.
• Applicants must also provide a curriculum vitae, a bibliography focused on the previous five years and relevant publications, and a list of current research support.
• Applications must be submitted electronically through the CRI application portal. Supporting documents must be submitted individually as PDFs, using single spacing and a font size of at least 12 points.
• Official program information and application details: Visit the Cancer Research Institute website for the current Lloyd J. Old STAR Program guidelines, eligibility requirements, application resources, and program updates.

4. Kidney Cancer Early-Career Scholar Award 2026

The FY26 Kidney Cancer Research Program Academy of Kidney Cancer Investigators – Early-Career Scholar Award supports promising researchers and physician-scientists pursuing independent careers in kidney cancer research.

Recipients join the virtual Academy of Kidney Cancer Investigators, which provides intensive mentorship, national networking, scientific collaboration, leadership development, and a peer community of early-career kidney cancer researchers. Scholars conduct a four-year research project under the guidance of an established kidney cancer investigator and participate in monthly virtual meetings and required in-person Academy workshops.

Eligibility Criteria:

• Applicants must be independent early-career researchers or physician-scientists affiliated with an eligible organization.
• Applicants must have approximately 50% institutional protected time for kidney cancer research and Academy activities.
• Applicants recommended for funding cannot hold a concurrent career-development-type award when the Kidney Cancer Research Program award is issued.
• Each applicant may serve as Principal Investigator on only one FY26 Early-Career Scholar Award application.
• Applicants must identify a Designated Mentor who is an independent, established kidney cancer investigator with a strong record of publications, funding, and successful mentorship.
• The institutional mentor must be an independent researcher with relevant expertise and a record of cancer research funding but is not required to specialize in kidney cancer.
• There are no citizenship, nationality, or ethnicity restrictions.

Funding Details:

• The maximum award amount is USD 1.2 million in total costs.
• The maximum project period is four years.
• Approximately USD 2.4 million is expected to support around two Early-Career Scholar Awards.
• Both direct and indirect costs must be included within the USD 1.2 million total-cost limit.
• Funding may support salaries for the Early-Career Scholar, Designated Mentor, institutional mentor, and research staff.
• Tuition and clinical-trial expenses are not eligible.

Deadline:

• Required Letter of Intent deadline: September 14, 2026, at 5:00 p.m. Eastern Time.
• Full application deadline: September 28, 2026, at 11:59 p.m. Eastern Time.
• Application verification period ends: October 5, 2026, at 5:00 p.m. Eastern Time.
• Peer review: December 2026.
• Awards are expected to be issued no later than September 30, 2027.

Further Information:

• Projects may involve basic, translational, or clinical research, but clinical trials are not allowed. Preliminary data demonstrating project feasibility are required, although the data do not need to come from kidney cancer research.
• Applications must address at least one FY26 Kidney Cancer Research Program focus area, such as kidney cancer biology, early detection, rare kidney cancers, less toxic treatments, survivorship, health outcomes, or development of the next generation of kidney cancer investigators.
• The application process requires a one-page Letter of Intent through eBRAP followed by a complete full application; the LOI is mandatory but is used for planning rather than competitive screening, and applicants do not need to wait for an invitation.
• The full application requires a Project Narrative, Career Development and Sustainment Plan, technical and lay abstracts, Impact Statement, Statement of Work, mentor letters, Statement of Eligibility, budget, biosketches, and current and pending support.
• Official program information and application details: Visit the CDMRP funding opportunities page and search for Funding Opportunity Number HT942526KCRPAKCIECSA to access the complete announcement, submission portals, application forms, General Application Instructions, and current updates.

5. Cholangiocarcinoma Foundation Innovation Award 2027

The 2027 Cholangiocarcinoma Foundation (CCF) Innovation Award supports ambitious, collaborative research focused on Biomarkers for the Early Diagnosis of Cholangiocarcinoma.

The award seeks multi-institutional projects identifying, refining, or evaluating blood-based, bile-based, imaging-based, or other biomarkers with the potential to improve early detection and ultimately patient outcomes. The 2027 RFP states that this opportunity is made available with support from the Julienne Morriss Callaway Memorial Research Fund.

Eligibility Criteria:

• Applicants may hold an MD, PhD, PharmD, DVM, or equivalent research qualification.
• Applicants may be based at academic, medical, or research institutions anywhere worldwide.
• Proposals must involve a multi-center collaboration of at least two institutions/sites.
• Previous recipients of CCF grants are eligible to apply.
• Not every collaborator is required to have previous experience in cholangiocarcinoma research.
• There are no applicant restrictions based on age, gender, race, disability, nationality, or country of residence.

Funding Details:

• The award provides a total funding commitment of USD 750,000.
• The RFP states that funding will be distributed in annual installments of USD 250,000.
• One Innovation Award is expected to be made.
• Salary and benefits of grant recipients may be included.
• Institutional indirect costs and overhead are not permitted.

Deadline:

• Letter of Intent deadline: September 4, 2026, at 11:59 p.m. U.S. Eastern Time.
• LOI outcome/invitations to submit a full application: September 25, 2026.
• Invited full application deadline: October 28, 2026.
• Scientific merit review: November 20, 2026.
• Award notification: November 30, 2026.
• Earliest project start date: June 1, 2027.

Further Information:

• Eligible biomarker research may investigate blood-based biomarkers, bile-based biomarkers, imaging-based biomarkers, or biomarkers derived from other biospecimens such as stool or saliva.
• LOIs must include a two-page research summary covering the project, specific aims, rationale, scientific approach, significance, and innovation; a one-page reference list; and an NIH biosketch or CV of up to three pages for each collaborator.
• Applications should demonstrate potential impact on patient outcomes, hypothesis-driven aims, appropriate statistical rigor, feasibility within the award period, and meaningful development of an Early Career Researcher. Note: the 2027 RFP describes a three-year USD 750,000 funding commitment but separately lists the research focus period as June 1, 2027–May 31, 2029; applicants should confirm the intended project duration with CCF.
• Official program information and application details: Visit the Cholangiocarcinoma Foundation research funding page and submit applications through ProposalCentral. The Foundation’s general Innovation Award information also confirms funding of USD 750,000 over three years.
• Download the official program document: Download the 2027 CCF Innovation Award Call for Letters of Intent.

6. CRI IGNITE Award 2027

The CRI IGNITE Award supports promising postdoctoral researchers as they transition from mentored training to independent research careers in cancer immunology and immunotherapy.

The award combines up to two years of postdoctoral support with up to three additional years of funding after the researcher secures an independent faculty position. The program emphasizes protected research time, mentorship, career development, and institutional support needed to establish a successful independent research program.

Eligibility Criteria:

• Applicants must be in a mentored postdoctoral position at the time of application.
• Applicants should have no more than five years of postdoctoral experience when applying.
• Applicants must commit to at least 12 months of mentored research before transitioning to the independence phase.
• There are no citizenship restrictions.
• The program is intended for researchers pursuing careers relevant to cancer immunology and immunotherapy.
• To enter Phase 2, awardees must first have received support through the IGNITE Foundation Phase.
• Phase 2 applicants must secure and accept a full-time tenure-track Assistant Professor position or equivalent.

Funding Details:

• Maximum combined support: USD 1.05 million over up to five years.
• Phase 1 – Foundation Phase: up to USD 150,000 per year for two years, or USD 300,000 total.
• Phase 1 includes USD 90,000 per year in salary support and USD 60,000 per year for independent research activities.
• Phase 2 – Independence Phase: up to USD 250,000 per year for three years, or USD 750,000 total.
• Phase 2 funding begins after the awardee secures an eligible independent faculty appointment.
• Phase 2 support is contingent on the hiring institution providing an adequate start-up package.

Deadline:

• Application deadline: January 11, 2027, at 11:59 p.m. Eastern Time.
• Applicants are expected to receive committee decisions approximately 10–12 weeks after the application deadline.

Further Information:

• Applications require a CV and bibliography, research background and accomplishments, selected publications, career goals, and a structured Career Development Plan describing the applicant’s pathway toward research independence.
• Applicants must submit a research plan covering both the mentored and independent phases, including the significance, innovation, approach, expected outcomes, and how Phase 1 research will enable development of an independent program.
• The primary mentor must provide a detailed support statement describing mentorship, professional-development activities, supervision, and plans to help the applicant transition to an independent position.
• Two additional letters of recommendation are required from individuals other than the applicant’s primary mentor, along with mentor biosketches and information on current research support.
• Official program information and application details: Visit the CRI IGNITE Award page for eligibility requirements, application materials, funding details, and access to the application portal.

7. CRI Clinical Innovator Grant 2026–2027

The CRI Clinical Innovator supports innovative investigator-initiated clinical trials that advance cancer immunotherapy and generate insights capable of improving patient care.

The program focuses on Phase I/II and Phase II clinical studies testing novel immunotherapy approaches, investigating mechanisms of clinical response, and discovering or validating predictive biomarkers. Competitive proposals should combine strong clinical trial design with rigorous biospecimen collection, correlative research, and data analysis. (Cancer Research Institute)

Eligibility Criteria:

• The applicant must serve as the Principal Investigator of the proposed clinical study.
• Institutions may be located in the United States or internationally.
• There are no citizenship restrictions.
• The proposed project should be an innovative Phase I/II or Phase II clinical study.
• Applications should incorporate appropriate sample collection, correlative assays, and advanced data-analysis strategies.
• Multiple scientifically distinct applications from the same institution are permitted under CRI’s general policies.
• Applicants may submit proposals to other funders simultaneously, but overlapping funding cannot be accepted for the same work. (Cancer Research Institute)

Funding Details:

• The program provides up to USD 1,000,000 per clinical trial.
• Funding may support investigator salary.
• Eligible expenses may include patient-related costs.
• Data analysis costs may be included.
• Institutions may receive indirect costs of up to 10% of the awarded amount.
• Therefore, a project receiving the maximum award could potentially receive up to approximately USD 1.1 million including allowable indirect costs.

Deadline:

• Initial Protocol Concept deadline: December 1, 2026, at 11:59 p.m. Eastern Time.
• Invitation decisions: By late February 2027.
• Invited full proposal deadline: April 9, 2027, at 11:59 p.m. Eastern Time.

Further Information:

• Initial submissions require a protocol concept of up to two pages describing the study rationale, objectives, patient population, eligibility, sample collection, and biostatistical plan, plus a separate one-page study schema.
• Applicants must also submit a translational research plan of up to one page and biosketches for the PI and any co-PIs; supporting documents must be uploaded individually as PDFs.
• CRI evaluates proposals based on novelty, feasibility, scientific rationale, translational rigor, and potential for meaningful clinical impact.
• A special opportunity with the Chordoma Foundation supports qualifying clinical research aimed at developing effective treatments for chordoma, with successful projects co-funded by CRI and the Foundation.
• Official program information and application details: Visit the CRI Clinical Innovator page for current eligibility requirements, application instructions, supporting materials, deadlines, and access to the application portal.

8. Conquer Cancer Research Professorship 2027

The Conquer Cancer Research Professorship provides flexible funding to outstanding senior physician-scientists who have made significant contributions to cancer research and are committed to training the next generation of oncology leaders.

Recipients may use the funding to strengthen their overall research programs, lead multidisciplinary research teams, and support the development of oncology trainees and junior faculty. Individual Research Professorship competitions may be dedicated to specific cancer types or research areas.

Eligibility Criteria:

• Applicants must be physicians holding an MD, DO, or international equivalent.
• Applicants must currently hold the rank of Full Professor or its institutional equivalent.
• Applicants who do not formally hold the rank of Full Professor must provide a written explanation demonstrating why their position should be considered equivalent.
• Applicants must continue providing research leadership and mentorship throughout the award period.
• Applicants must commit at least 75% of their professional time to research, research-team leadership, and mentorship during the award period.
• Applicants may hold only one active Conquer Cancer grant at a time.

Funding Details:

• The current Research Professorship funding structure provides USD 500,000 over five years.
• Funding is generally paid in annual installments of USD 100,000.
• The award offers flexible support that may be used to strengthen the recipient’s overall cancer-research activities.
• Exact budget restrictions, indirect-cost limits, and eligible expenses are defined in each topic-specific Request for Proposals.

Deadline:

• For the dedicated 2027 ovarian cancer competition, the Letter of Intent deadline is September 23, 2026.
• Deadlines vary according to the dedicated research area and annual Request for Proposals.
• Applicants should review the current Conquer Cancer funding-opportunity listings for available competitions.
• Ovarian cancer eligibility and application details are covered in a separate funding post.

Further Information:

• Research Professorship competitions may focus on specific cancer types or priority research areas.
• Applicants should carefully review the topic-specific RFP because geographic eligibility, research focus, budget rules, and deadlines may differ.
• Applications generally assess the applicant’s research accomplishments, team leadership, mentoring record, institutional resources, and proposed scientific impact.
• All application materials must be prepared in English and submitted through the ASCO and Conquer Cancer Application Portal; email, fax, and paper submissions are not accepted.
• Current opportunities are listed on the official Conquer Cancer funding opportunities page, and eligibility questions may be sent to grants@conquer.org.

9. Lymphoma Research Foundation Clinical Investigator Career Development Award 2027

The Lymphoma Research Foundation Clinical Investigator Career Development Award supports advanced fellows and junior faculty members preparing for independent careers in lymphoma clinical research.

The award helps physician investigators develop and lead clinical studies focused on new lymphoma therapies and diagnostic tools. Projects must be hypothesis-driven and primarily clinical, although related translational research aims may also be included.

Eligibility Criteria:

• Applicants must be pursuing a career in lymphoma clinical research.
• Eligible clinical specialties include hematology/oncology, pediatrics, pathology, dermatology, radiation oncology, and other relevant accredited specialties.
• Applicants must have completed at least 24 months of fellowship or postdoctoral training.
• Applicants may have no more than six years of experience beyond completion of fellowship or postdoctoral training as of March 1, 2027.
• Applicants must commit between 35% and 50% of their professional time to lymphoma clinical research, free from major clinical, teaching, and administrative responsibilities.
• U.S. or Canadian citizenship or permanent residency is not required for the general award.
• Recipients may not simultaneously hold another career development award, including NIH K-series awards or comparable grants primarily supporting the Principal Investigator’s salary.

Funding Details:

• The award provides USD 375,000 over three years.
• Salary support is provided at USD 120,000 per year.
• An additional USD 5,000 per year may support research supplies or professional-development expenses.
• The applicant must dedicate between 35% and 50% of their time to the proposed clinical research and career-development activities.

Deadline:

• Application release date: June 1, 2026.
• Application deadline: September 3, 2026, at 5:00 p.m. Eastern Standard Time.
• Peer-review period: September–November 2026.
• Funding decision notification: By December 18, 2026.
• Earliest project start date: March 1, 2027.
• Latest project start date: July 1, 2027.

Further Information:

• Research must focus on lymphoma or chronic lymphocytic leukemia and cannot combine these diseases with cancers or hematologic malignancies outside the recognized lymphoma classification. At least one clinical research aim must be the project’s primary focus.
• Applicants must submit a two-page Career Development Plan describing the training, educational activities, mentorship, research skills, and publication strategy that will support progression toward research independence.
• A primary institutional mentor is required, and applicants may include up to four associate mentors with complementary expertise. Three additional blinded letters of support are also required.
• Official program information and application details: Visit the Lymphoma Research Foundation grants page for the current RFP, award policies, related resources, and ProposalCentral application information.
• Download the official program document: Download the 2027 Clinical Investigator Career Development Award RFP.

10. CRI Technology Impact Award 2026

The CRI Technology Impact Award supports bold, early-stage technological concepts that have not yet been built or tested but could transform cancer immunotherapy research and patient care.

The program bridges conceptual innovation and clinical application by supporting proof-of-principle development of new tools, platforms, devices, algorithms, and systems. Projects should address major technological barriers in understanding, detecting, or treating cancer through the immune system.

Eligibility Criteria:

• Applicants must hold a tenure-track position at a nonprofit research centre or institution.
• Co-Principal Investigators are eligible and encouraged to apply.
• Applications that simply use established technologies, such as single-cell or spatial sequencing, without substantial device, instrumentation, platform, or algorithm development will generally not be considered responsive.
• Projects should demonstrate novelty, creativity, technical sophistication, and transformative potential.
• Clinical trials are not supported through this award.
• Samples collected through independently funded clinical trials may be used when relevant to the proposed technology-development project.

Funding Details:

• The award provides up to USD 600,000 in research funding.
• The funding period may range from two to four years.
• Institutional indirect costs of up to 10% of the awarded amount may be provided in addition to the research funding.
• A project receiving the full USD 600,000 may therefore receive up to an additional USD 60,000 in indirect costs.
• The maximum potential institutional support is approximately USD 660,000, including allowable indirect costs.
• The earliest possible award activation date is July 1, 2027.

Deadline:

• Letter of Intent deadline: November 16, 2026, at 11:59 p.m. Eastern Time.
• Invitation decisions: By mid-February 2027.
• Invited full proposal deadline: March 12, 2027, at 11:59 p.m. Eastern Time.
• Earliest award activation: July 1, 2027.

Further Information:

• Priority technologies may include computational systems-biology platforms, advanced molecular profiling tools, real-time immune-response visualization, complex multicellular culture systems, and novel therapeutic technologies.
• Letters of Intent must include a research concept of no more than three pages, a description of the applicant’s current research, a curriculum vitae, a recent or relevant bibliography, and applicable materials for additional team members.
• Attached documents must be submitted individually as PDFs, use single spacing and a font size of at least 12 points, and comply with all stated page limits.
• Questions or technical problems involving application attachments may be directed to the CRI grants team through the contact information provided on the program page.
• Official program information and application details: See the official CRI Technology Impact Award page for the application portal, eligibility rules, supporting documents, deadlines, and application resources.

Bookmark this list, share it with your network, and check back each week for the latest curated OncoGrants opportunities on OncoDaily.